Treatment schema and aGVHD. (A) Treatment schema. (B) Maximal grade of aGVHD among evaluable patients (n = 5 each for DL1 and DL3; n = 20 for DL2). Patients without aGVHD but with death, graft failure, or relapse before day +60 were not included, as per the protocol these patients were considered inevaluable for the primary endpoint.